Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : NEOTHERAPEUTICS (NEOT) (NEOTW) -- Ignore unavailable to you. Want to Upgrade?

To: Marty who wrote (481)	6/10/1998 6:02:00 PM
From: Marty	Respond to of 705

Report on the Dr. Glasky interview: It had to be the short sellers' worst nightmare come true. All the seemingly inconsistent statements and all the allegations that the short sellers' could create over them were answered straightforwardly in the interview. When he was asked about which patients improved, Dr. Glasky explained that the tests were double blinded and that some of the patients were on placebos. All the patients that were given AIT 082 improved. (It looks like the company was excessively cautious by saying that not everybody improved. Those on placebos didn't necessarily improve.) When asked about whether they would need more financing, he explained that they had enough to get them through the current phase but that if everything worked out in the tests and they went on to the next phase, more financing would be necessary. They are putting a deal with a pharma on the back burner because they don't currently need the three things a partnership would give them. They don't need the money right now as that is arranged already for this phase. They don't need the technology help because they are doing fine with that now without help. They will need help with the marketing later on but that is premature now and they will be able to get better terms after Phase II. He described again what the drug does and why it is so unique. He also listed the other diseases and injuries that NEOT targeted with drugs that I believe are in the same AIT 082 family. They are currently developing and testing drugs for dementia, spinal cord injuries, stroke, Parkinson's, Disease and migraines. Next steps for AIT 082 are more analysis of the first tests, a bigger study (now underway) to determine lasting effects, and further efficacy tests.